Cited 12 times in
Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 어경진 | - |
dc.contributor.author | 이정윤 | - |
dc.date.accessioned | 2018-07-20T08:51:53Z | - |
dc.date.available | 2018-07-20T08:51:53Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161411 | - |
dc.description.abstract | In epithelial ovarian cancer (EOC), intraperitoneal (IP) administration of chemotherapy is an effective first-line treatment and may improve outcomes, compared with intravenous (IV) chemotherapy. We used Kaplan-Meier survival analysis to compare long-term survival between propensity score-matched patients with advanced EOC receiving IP (n = 34) vs. IV (n = 68) chemotherapy. Additionally, clinical features associated with carboplatin-based (n = 21) and cisplatin-based (n = 16) IP chemotherapy were analyzed and compared with those associated with IV chemotherapy. The IP and IV chemotherapy groups had a median follow-up duration of 67 (range, 3-131) and 62 (range, 0-126) months, respectively, with no significant difference in progression-free survival (PFS) (P = 0.735) and overall survival (OS) (P = 0.776). A significantly higher proportion of patients in the IV (91.2%) than in the IP (67.6%) chemotherapy group (P = 0.004) received ≥ 6 cycles. However, the frequency of toxic events (anemia, granulocytopenia, nausea/vomiting, abdominal pain, hepatotoxicity, neuromuscular effects) was significantly higher in the IP than in the IV group. Within the IP group, no significant differences were observed in PFS (P = 0.533) and OS (P = 0.210) between the cisplatin-based and carboplatin-based chemotherapy subgroups. The 10-year OS was 28.6% and 49.2% in carboplatin-based and cisplatin-based IP chemotherapy groups, respectively. Toxic events (granulocytopenia, leukopenia, nausea/vomiting, abdominal pain, hepatotoxicity, neuromuscular effects) were significantly more common in the cisplatin-based subgroup. In patients with EOC, cisplatin-based IP chemotherapy may be an acceptable alternative to IV chemotherapy regarding long-term survival, but toxicity must be addressed. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | 대한의학회(The Korean Academy of Medical Sciences) | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Agranulocytosis/etiology | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Carboplatin/adverse effects | - |
dc.subject.MESH | Carboplatin/therapeutic use* | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Cisplatin/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous/methods* | - |
dc.subject.MESH | Injections, Intraperitoneal/methods* | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nausea/etiology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Ovarian Neoplasms/drug therapy* | - |
dc.subject.MESH | Ovarian Neoplasms/mortality | - |
dc.subject.MESH | Ovarian Neoplasms/pathology | - |
dc.subject.MESH | Vomiting/etiology | - |
dc.title | Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology | - |
dc.contributor.googleauthor | Kyung Jin Eoh | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.identifier.doi | 10.3346/jkms.2017.32.12.2021 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A04842 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 29115086 | - |
dc.subject.keyword | Carboplatin | - |
dc.subject.keyword | Intraperitoneal Chemotherapy | - |
dc.subject.keyword | Ovarian Cancer | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.alternativeName | Nam, Eun Ji | - |
dc.contributor.alternativeName | Eoh, Kyung Jin | - |
dc.contributor.alternativeName | Lee, Jung-Yun | - |
dc.contributor.affiliatedAuthor | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Nam, Eun Ji | - |
dc.contributor.affiliatedAuthor | Eoh, Kyung Jin | - |
dc.contributor.affiliatedAuthor | Lee, Jung-Yun | - |
dc.citation.volume | 32 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2021 | - |
dc.citation.endPage | 2028 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.32(12) : 2021-2028, 2017 | - |
dc.identifier.rimsid | 61328 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.